BACKGROUND: Hypercalcemia is caused by many different conditions and may lead to severe complications. Loss-of-function mutations of CYP24A1, encoding vitamin D-24-hydroxylase, have recently been identified in idiopathic infantile hypercalcemia and in adult kidney stone disease. The aim of this study was to investigate the genetics and clinical features of both infantile and maternal hypercalcemia. METHODS: We studied members of four unrelated Israeli families with hypercalcemia, namely, one woman during pregnancy and after delivery and three infants. Clinical and biochemical data were obtained from probands' medical charts. Genomic DNA was isolated from peripheral blood and CYP24A1 was sequenced. RESULTS: Typical symptoms of hypercalcemia associated with the intake of recommended doses of vitamin D developed in the infants and pregnant woman. Four different loss-of-function CYP24A1 mutations were identified, two of which are reported here for the first time (p.Trp134Gly and p.Glu315*). The infants from families 1 and 2, respectively, were found to be compound heterozygotes, and the infant from family 3 and the pregnant woman were found to be homozygous. CONCLUSIONS: This is the first report of maternal hypercalcemia caused by a CYP24A1 mutation, showing that not only infants are at risk for this complication. Our findings emphasize the importance of recognition, genetic diagnosis and proper treatment of this recently identified hypercalcemic disorder in this era of widespread vitamin D supplements.
BACKGROUND:Hypercalcemia is caused by many different conditions and may lead to severe complications. Loss-of-function mutations of CYP24A1, encoding vitamin D-24-hydroxylase, have recently been identified in idiopathic infantile hypercalcemia and in adult kidney stone disease. The aim of this study was to investigate the genetics and clinical features of both infantile and maternal hypercalcemia. METHODS: We studied members of four unrelated Israeli families with hypercalcemia, namely, one woman during pregnancy and after delivery and three infants. Clinical and biochemical data were obtained from probands' medical charts. Genomic DNA was isolated from peripheral blood and CYP24A1 was sequenced. RESULTS: Typical symptoms of hypercalcemia associated with the intake of recommended doses of vitamin D developed in the infants and pregnant woman. Four different loss-of-function CYP24A1 mutations were identified, two of which are reported here for the first time (p.Trp134Gly and p.Glu315*). The infants from families 1 and 2, respectively, were found to be compound heterozygotes, and the infant from family 3 and the pregnant woman were found to be homozygous. CONCLUSIONS: This is the first report of maternal hypercalcemia caused by a CYP24A1 mutation, showing that not only infants are at risk for this complication. Our findings emphasize the importance of recognition, genetic diagnosis and proper treatment of this recently identified hypercalcemic disorder in this era of widespread vitamin D supplements.
Authors: R St-Arnaud; A Arabian; R Travers; F Barletta; M Raval-Pandya; K Chapin; J Depovere; C Mathieu; S Christakos; M B Demay; F H Glorieux Journal: Endocrinology Date: 2000-07 Impact factor: 4.736
Authors: S Khosla; J A van Heerden; H Gharib; I T Jackson; J Danks; J A Hayman; T J Martin Journal: N Engl J Med Date: 1990-04-19 Impact factor: 91.245
Authors: Andrew Dauber; Thutrang T Nguyen; Etienne Sochett; David E C Cole; Ronald Horst; Steven A Abrams; Thomas O Carpenter; Joel N Hirschhorn Journal: J Clin Endocrinol Metab Date: 2011-11-23 Impact factor: 5.958
Authors: Michalis K Picolos; Charles R Sims; Joan M Mastrobattista; Mary A Carroll; Victor R Lavis Journal: Obstet Gynecol Date: 2004-11 Impact factor: 7.661
Authors: Peter J Tebben; Dawn S Milliner; Ronald L Horst; Peter C Harris; Ravinder J Singh; Yanhong Wu; John W Foreman; Paul R Chelminski; Rajiv Kumar Journal: J Clin Endocrinol Metab Date: 2012-02-15 Impact factor: 5.958
Authors: Gina N Woods; Alec Saitman; Hanlin Gao; Nigel J Clarke; Robert L Fitzgerald; Nai-Wen Chi Journal: J Bone Miner Res Date: 2016-05-06 Impact factor: 6.741
Authors: Arti D Shah; Edward C Hsiao; Betsy O'Donnell; Kirsten Salmeen; Robert Nussbaum; Michael Krebs; Sabina Baumgartner-Parzer; Martin Kaufmann; Glenville Jones; Daniel D Bikle; YongMei Wang; Allen S Mathew; Dolores Shoback; Ingrid Block-Kurbisch Journal: J Clin Endocrinol Metab Date: 2015-06-22 Impact factor: 5.958
Authors: Nina Lenherr-Taube; Edwin J Young; Michelle Furman; Yesmino Elia; Esther Assor; David Chitayat; Tami Uster; Susan Kirwin; Katherine Robbins; Kathleen M B Vinette; Alan Daneman; Christian R Marshall; Carol Collins; Kenneth Thummel; Etienne Sochett; Michael A Levine Journal: J Clin Endocrinol Metab Date: 2021-09-27 Impact factor: 6.134